SELLAS Life Sciences Group (SLS) Competitors $0.91 +0.02 (+2.38%) (As of 12/23/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SLS vs. ATYR, MRSN, CMRX, HRTX, FULC, ACB, FATE, LXEO, DMAC, and ZNTLShould you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include Atyr PHARMA (ATYR), Mersana Therapeutics (MRSN), Chimerix (CMRX), Heron Therapeutics (HRTX), Fulcrum Therapeutics (FULC), Aurora Cannabis (ACB), Fate Therapeutics (FATE), Lexeo Therapeutics (LXEO), DiaMedica Therapeutics (DMAC), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical products" industry. SELLAS Life Sciences Group vs. Atyr PHARMA Mersana Therapeutics Chimerix Heron Therapeutics Fulcrum Therapeutics Aurora Cannabis Fate Therapeutics Lexeo Therapeutics DiaMedica Therapeutics Zentalis Pharmaceuticals SELLAS Life Sciences Group (NASDAQ:SLS) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment. Which has more volatility and risk, SLS or ATYR? SELLAS Life Sciences Group has a beta of 2.39, suggesting that its stock price is 139% more volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Does the media favor SLS or ATYR? In the previous week, Atyr PHARMA had 2 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 2 mentions for Atyr PHARMA and 0 mentions for SELLAS Life Sciences Group. Atyr PHARMA's average media sentiment score of 0.59 beat SELLAS Life Sciences Group's score of 0.00 indicating that Atyr PHARMA is being referred to more favorably in the news media. Company Overall Sentiment SELLAS Life Sciences Group Neutral Atyr PHARMA Positive Do analysts rate SLS or ATYR? Atyr PHARMA has a consensus price target of $19.25, indicating a potential upside of 469.53%. Given Atyr PHARMA's stronger consensus rating and higher possible upside, analysts clearly believe Atyr PHARMA is more favorable than SELLAS Life Sciences Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SELLAS Life Sciences Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Atyr PHARMA 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer SLS or ATYR? SELLAS Life Sciences Group received 1 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 55.56% of users gave SELLAS Life Sciences Group an outperform vote. CompanyUnderperformOutperformSELLAS Life Sciences GroupOutperform Votes1055.56% Underperform Votes844.44% Atyr PHARMAOutperform Votes9100.00% Underperform VotesNo Votes Is SLS or ATYR more profitable? Atyr PHARMA's return on equity of -79.44% beat SELLAS Life Sciences Group's return on equity.Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences GroupN/A -629.46% -178.65% Atyr PHARMA N/A -79.44%-59.16% Which has higher earnings and valuation, SLS or ATYR? SELLAS Life Sciences Group has higher revenue and earnings than Atyr PHARMA. Atyr PHARMA is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSELLAS Life Sciences Group$1M63.98-$37.34M-$0.69-1.32Atyr PHARMA$235K1,207.34-$50.39M-$0.94-3.60 Do insiders & institutionals have more ownership in SLS or ATYR? 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are owned by institutional investors. 1.2% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 3.7% of Atyr PHARMA shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryAtyr PHARMA beats SELLAS Life Sciences Group on 11 of the 17 factors compared between the two stocks. Ad Prosper Trading AcademyA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading system finds high-probability option trades in less than 60 seconds a dayClick HERE to access this powerful AI Trading System Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLS vs. The Competition Export to ExcelMetricSELLAS Life Sciences GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.98M$6.69B$5.20B$9.15BDividend YieldN/A3.00%5.12%4.30%P/E Ratio-1.3210.4887.2017.10Price / Sales63.98193.661,149.06122.70Price / CashN/A57.1643.2337.84Price / Book-3.645.134.804.78Net Income-$37.34M$151.58M$120.46M$225.43M7 Day Performance3.11%-1.40%-0.92%-0.78%1 Month Performance-22.30%-3.69%14.99%1.05%1 Year Performance-10.87%9.07%29.63%15.79% SELLAS Life Sciences Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLSSELLAS Life Sciences Group0.0096 of 5 stars$0.91+2.4%N/A-10.9%$63.98M$1M-1.3216Gap UpATYRAtyr PHARMA2.4878 of 5 stars$3.11+1.6%$19.25+519.0%N/A$261.06M$235,000.00-3.2656MRSNMersana Therapeutics4.3186 of 5 stars$2.10-2.3%$6.00+185.7%-24.3%$259.41M$36.85M-3.52150Positive NewsCMRXChimerix4.0798 of 5 stars$2.87-2.7%$8.50+196.2%+224.3%$258.13M$320,000.00-3.1472Gap UpHRTXHeron Therapeutics3.9588 of 5 stars$1.66+3.8%$5.67+241.4%-10.6%$252.48M$137.74M-8.89300Gap DownFULCFulcrum Therapeutics1.708 of 5 stars$4.42+11.6%$9.33+111.2%-25.5%$238.41M$80.87M-13.68100ACBAurora Cannabis0.0989 of 5 stars$4.29-0.5%N/A-11.1%$235.26M$200.35M-5.671,073FATEFate Therapeutics3.5725 of 5 stars$2.05+12.0%$6.75+229.3%-51.5%$233.48M$13.45M-1.22550LXEOLexeo Therapeutics2.8 of 5 stars$6.99+1.6%$23.80+240.5%-60.1%$231.13M$650,000.00-2.1858DMACDiaMedica Therapeutics1.7333 of 5 stars$5.37-0.2%$7.00+30.4%+88.8%$229.62MN/A-9.6120Gap DownZNTLZentalis Pharmaceuticals2.0084 of 5 stars$3.22+4.2%$10.00+210.6%-77.9%$229.46MN/A-1.24160Positive NewsGap Up Related Companies and Tools Related Companies Atyr PHARMA Alternatives Mersana Therapeutics Alternatives Chimerix Alternatives Heron Therapeutics Alternatives Fulcrum Therapeutics Alternatives Aurora Cannabis Alternatives Fate Therapeutics Alternatives Lexeo Therapeutics Alternatives DiaMedica Therapeutics Alternatives Zentalis Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLS) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLS Stock Alerts